Proteintech Genomics Launches First Commercially Available Solution for the Detection of Intracellular Proteins for Single-Cell RNAseq Experiments
Proteintech Genomics, a subsidiary of Proteintech Group, Inc., and a provider of multiomic solutions for single-cell and spatial analysis, announced the launch of the MultiPro™Human Fixed Cell Immune Profiling Antibody Cocktail. This cocktail contains 53 antibodies against intracellular and cell surface proteins, plus 5 isotype controls. The pre-titrated cocktail is demonstrated to be compatible with the 10x Genomics® Chromium® Single Cell Gene Expression Flex product.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231106129354/en/
Proteintech Genomics' MultiPro™ Human Fixed Cell Immune Profiling Antibody Cocktail containing 53 antibodies against intracellular and cell surface proteins, plus 5 isotype controls (Photo: Business Wire)
CEO of Proteintech Genomics, Kit Nazor, states, “With techniques like CITE-seq, it has been possible to layer highly multiplexed cell surface protein data on top of single cell gene expression profiles, but intracellular proteins have remained out of reach. We have been working diligently to provide researchers with the ability to delve beyond the cell surface and provide a high resolution view of intracellular proteins in addition to cell surface proteins and gene expression. Our MultiPro™ antibodies will empower researchers to push the boundaries of what we can learn from single cell studies.”
Peter Smibert, VP of Biology at 10x Genomics, said, “In my pre-10x days, my lab developed CITE-seq to measure surface proteins with single cell transcriptomes. While several groups have subsequently obtained believable signal from intracellular proteins coupled with single cell gene expression, the resulting data was suboptimal. Proteintech Genomics’ MultiPro Immune Profiling Cocktail together with 10x’s Chromium Single Cell Gene Expression Flex assay is a game changer, unlocking protein detection throughout the whole cell – surface, cytoplasm and nucleus – and delivered with the high-quality gene expression data we expect from Flex.”
The MultiPro Human Fixed Cell Immune Profiling Antibody Cocktail was developed solely for use with products sold by 10x Genomics, Inc. The cocktail will begin shipping November 6, 2023. For more information, please visit Proteintech Genomics. Inquiries should be directed to: firstname.lastname@example.org.
About Proteintech Genomics®
Proteintech Genomics is a life science technology company empowering the research community with powerful tools to unlock the discovery potential of single cell and spatial multiomics. The company is developing highly multiplexed and fully optimized proteomic assays that can be readily integrated into various single cell and spatial analysis application workflows. Proteintech Genomics was founded as a subsidiary of the Proteintech Group in 2022 and opened its state-of-the-art San Diego facility in July 2022.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
About Proteintech Group
Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. With over 200,000 products cited and confirmed specificity, Proteintech offers antibodies and immunoassays across research areas. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited. To learn more about Proteintech, please visit www.ptglab.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Evolito First in UK to Secure CAA Design Organisation Approval for Electric Propulsion Systems5.12.2023 09:00:00 CET | Press release
Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics and battery solutions for aerospace applications, has received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231201483295/en/ Evolito’s D500 Axial Flux Motor: stacked for increased torque and power up to 1 megawatt. (Photo: Business Wire) The UK Civil Aviation Authority’s approval of Evolito as a Design Organisation demonstrates that it is satisfied that Evolito has the technical expertise, facilities and capabilities to design safe and reliable products, and is able to comply with stringent requirements for certification. Evolito is the first company in the UK to achieve this for electric propulsion systems. This accreditation is a significant milestone towards certification of Evolito’s products, as well as supporting cu
PUMA Scale-up Their Textile-to-textile Recycling Technology, Creating All Future Replica Football Kit Using RE:FIBRE Technology5.12.2023 09:00:00 CET | Press release
Global sports company PUMA has today announced that it has scaled up its textile recycling innovation, RE:FIBRE, replacing recycled polyester with RE:FIBRE technology in all PUMA football Club and Federation replica jerseys from 2024 onwards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205250478/en/ Global sports company PUMA has today announced that it has scaled up its textile recycling innovation, RE:FIBRE, replacing recycled polyester with RE:FIBRE technology in all PUMA football Club and Federation replica jerseys from 2024 onwards. (Photo: Business Wire) Since the launch of the pilot in 2022, which saw PUMA produce recycled training jerseys for their sponsored football clubs, RE:FIBRE technology has been used to create Switzerland and Morocco replica kits for the Women’s World Cup as well as Girona’s 2023/24 season Third kit. In 2024, official PUMA football replica jerseys* including those for the Euro and Copa A
Taulia Adds Bank of China and BNP Paribas to Its Funder Network5.12.2023 09:00:00 CET | Press release
Taulia, a leading provider of working capital management solutions, today announced it has added the Bank of China London Branch, and BNP Paribas to its global multi-funder network. The addition of the two major global banks is the most recent in an already large and growing network of funders available to Taulia’s global customers, enabling businesses to access an increasingly broad and diverse funding pool, with greater choice, liquidity, and availability of capital. Multifunder models within supply chain finance programs are designed to provide resilience through diversification and a wider pool of funding for different currencies, geographies, client sizes, and credit profiles. Combined with the right technology, it also enables businesses to hedge against liquidity risk, particularly during periods of economic uncertainty. Cedric Bru, CEO, Taulia, comments: “Adding Bank of China and BNP Paribas to the Taulia multi-funder network is an enormous achievement, and we are delighted to
FPT Software Joins Global Tech Giants in the AI Alliance as Founding Member5.12.2023 07:00:00 CET | Press release
FPT Software, a global leading IT provider, announced its participation in the AIAlliance, a pivotal initiative formed by leading organizations across industry, startup, academia, research, and government with a shared goal of supporting open innovation and open science in AI. The alliance is expected to advance AI collaboration and foster innovation across all aspects of AI technology, applications, and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231204440838/en/ FPT Software Participates in the AI Alliance with Other Global Tech Giants (Photo: Business Wire) The Alliance, co-launched by IBM and Meta in collaboration with Founding Members globally, aims to leverage a critical mass of computing, data, tools, and talent to accelerate open innovation in AI to build and support open technologies across software, models, and tools, which empower students, developers, and scientists to understand and embrace open t
Wallarm Reveals Current Threats to API Security, Move to 100% Channel Strategy and New API Attack Management Solution at Black Hat Europe 20235.12.2023 07:00:00 CET | Press release
BLACK HAT EUROPE 2023 –Wallarm, the integrated app and API security company, today announced its upcoming appearance at Black Hat Europe 2023, the Dec. 4 to Dec. 7 conference that provides the latest in research, development and trends in information security. Wallarm executives are hosting a session on Dec. 7 at 12:15 p.m. GMT at ExCeL London and sharing critical insights and recommendations from the latest API ThreatStats™ report. Additionally, Wallarm is discussing its new 100% channel strategy and launching a new API Attack Surface Management solution during Black Hat Europe. Wallarm’s Black Hat appearance comes as interest in API security solutions grows in Europe, with the Europe API security market expected to witness market growth of 31.5% CAGR during the forecast period (2023-2030). This critical opportunity allows Wallarm to build awareness around the need for API and app security, jump-start expansion to the European market and recruit additional channel partners. Key announ